CAPRICOR THERAPEUTICS, INC. (CAPR)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | - | - | 2,261,642 | 3,971,438 |
| Research and development | 22,047,254 | 18,915,572 | 11,807,867 | 12,504,769 |
| General and administrative | 5,671,880 | 6,067,376 | 3,463,655 | 3,057,888 |
| Total operating expenses | 27,719,134 | 24,982,948 | 15,271,522 | 15,562,657 |
| Loss from operations | -27,719,134 | -24,982,948 | -13,009,880 | -11,591,219 |
| Loss on disposal of fixed assets | - | -150,673 | - | - |
| Other income | 14,991 | 12,485 | - | - |
| Investment income | 1,793,352 | 729,542 | 453,152 | 591,437 |
| Total other income (expense) | 1,808,343 | 591,354 | 453,152 | 591,437 |
| Net loss | -25,910,791 | -24,391,594 | -12,556,728 | -10,999,782 |
| Net unrealized gain (loss) on marketable securities | -424,353 | 784,972 | -58,766 | -152,714 |
| Comprehensive loss | -26,335,144 | -23,606,622 | -12,615,494 | -11,152,496 |
| Earnings per share, basic | -0.57 | -0.53 | -0.38 | -0.35 |
| Earnings per share, diluted | -0.57 | -0.53 | -0.38 | -0.35 |
| Weighted average number of shares outstanding, basic | 45,709,071 | 45,636,633 | 33,090,063 | 31,841,964 |
| Weighted average number of shares outstanding, diluted | 45,709,071 | 45,636,633 | 33,090,063 | 31,841,964 |